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Abstract 
OBJECTIVE: 
The Melasma Area and Severity Index (MASI) and the Melasma Severity Score (MSS) are calculated on the 
basis of only a subjective clinical assessment. This raises the need to have an objective score, uniform in the 
evaluation by different clinicians. The purpose of this study was to establish if the images by Canfield Reveal 
Imager can be correlated to MASI score to better evaluate the clinical efficacy of salicylic acid 33% peeling in 
the treatment of melasma respect to the clinical observation. 
METHODS: 
The study was a voluntary observational study. Twenty female patients affected with melasma, aged 
between 30 and 60 years, were included in the study. Treatment with salicylic acid 33% was performed once 
a month, for a total of four times. The dermatologist (Doc A) examined each patient's melasma areas using 
MASI score, at the face-to-face observation and at Reveal images evaluation during the first (T0) and the 
end point time (T4). Digital photographs were also evaluated by another experienced dermatologist (Doc B), 
who has never seen clinically the patients before and who evaluated MASI score by Reveal images at time 
T0 and T4. 
RESULTS: 
Student's t-test and linear regression test were performed, showing statistically significant values comparing 
MASI score obtained by digital photo and MASI score obtained clinically. 
CONCLUSION: 
The monitoring of the improvement by Reveal images can optimize the treatment approach and the efficacy 
of same dermocosmetics procedures can be revised following standard criteria. 
 
